Accession Number : ADA303254

Title :   Multidrug Resistance in Breast Cancer: Occurrence and Therapeutic Implications.

Descriptive Note : Annual rept. 1 Oct 94-30 Sep 95,

Corporate Author : UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES

Personal Author(s) : Muggia, Franco

PDF Url : ADA303254

Report Date : OCT 1995

Pagination or Media Count : 59

Abstract : We are continuing study of the therapeutic and biological implications of the overexpression of MDR1-Pglycoprotein in breast cancer. Two major thrusts have been initiated: (1) organizing a clinical trial of paclitaxel without and with reversal of MDR1-Pglycoprotein action with the cyclosporin analog PSC-833; and (2) study of P-glycoprotein immunostaining in patients with primary and metastatic breast cancer available through our tumor bank. In addition, we are pursuing technical development to confirm these studies can be done from fixed section. The clinical trial that is to start will be a definitive test of the hypothesis that MDR1 is an important factor in determining response to paclitaxel in advanced breast cancer, and that a potent reversal agent will have therapeutic efficacy, at least in MDRl overexpressing tumors. In addition, pharmacodynamic information in relation to paclitaxel without or with PSC-833 will be forthcoming.

Descriptors :   *CLINICAL MEDICINE, *GLYCOPROTEINS, *PHARMACOLOGY, *MAMMARY GLANDS, *BREAST CANCER, TEST AND EVALUATION, REVERSIBLE, THERAPY, HYPOTHESES, POTENCY, CANCER, METASTASIS.

Subject Categories : Medicine and Medical Research
      Pharmacology

Distribution Statement : APPROVED FOR PUBLIC RELEASE